{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=14", "query": { "intervention": "EXTEND", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 5818, "total_pages": 582, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T14:58:15.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07269873", "title": "Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Male and Female Volunteers" ], "interventions": [ { "name": "BICX104 naltrexone implantable pellet", "type": "DRUG" }, { "name": "Bupropion 150 mg XL", "type": "DRUG" }, { "name": "Naltrexone (depot)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCorRx Pharmaceuticals Inc", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2026-03-16", "completion_date": "2026-12-05", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07269873" }, { "nct_id": "NCT01379469", "title": "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alpha-1-antitrypsin Deficiency", "Liver Cirrhosis" ], "interventions": [ { "name": "Drug-Carbamazepine (Tegretol XR)", "type": "DRUG" }, { "name": "Carbamazepine (Tegretol XR) Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "14 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2012-01", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 3, "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379469" }, { "nct_id": "NCT07266805", "title": "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)" ], "interventions": [ { "name": "Deucrictibant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-10-16", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 4, "location_summary": "San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266805" }, { "nct_id": "NCT01640951", "title": "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Chronic Plaque-Type Psoriasis" ], "interventions": [ { "name": "AIN457 150 mg", "type": "DRUG" }, { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2012-09-16", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 28, "location_summary": "Fresno, California • Pasadena, California • San Francisco, California + 24 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640951" }, { "nct_id": "NCT02593773", "title": "Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Friedreich's Ataxia" ], "interventions": [ { "name": "Interferon γ-1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "10 Years to 26 Years" }, "enrollment_count": 86, "start_date": "2015-12-25", "completion_date": "2017-03-21", "has_results": true, "last_update_posted_date": "2024-12-19", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 4, "location_summary": "Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593773" }, { "nct_id": "NCT02972658", "title": "A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Lanabecestat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 421, "start_date": "2017-03-15", "completion_date": "2018-10-02", "has_results": true, "last_update_posted_date": "2019-12-03", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972658" }, { "nct_id": "NCT06025435", "title": "A Systems Analysis and Improvement Approach for Optimizing HIV Service Delivery in Syringe Services Programs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "SAIA-HIV-SSP", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-12-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06025435" }, { "nct_id": "NCT04016779", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 374, "start_date": "2019-11-20", "completion_date": "2020-10-10", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 37, "location_summary": "Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04016779" }, { "nct_id": "NCT03112603", "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Extracorporeal photopheresis (ECP)", "type": "DRUG" }, { "name": "Low-dose methotrexate (MTX)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 330, "start_date": "2017-06-29", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112603" }, { "nct_id": "NCT03070470", "title": "CiPA Phase 1 ECG Biomarker Validation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dofetilide and Diltiazem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2017-03-14", "completion_date": "2017-06-26", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-18T14:58:15.134Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070470" } ] }